To test whether blocking Cldn5 would open BBB to plasma, we administered M01 in GL261 tumor-bearing Rab27-proficient mice followed by contrast enhanced magnetic resonance imaging (MRI; Fig. 6G). Here, CLDN5 is linked to neoplasm.